Purpose: Oxidative stress-induced mitochondrial damage is the main event in acquired brain injuries (ABI). This study aimed to evaluate the effects of melatonin, a mitochondria-targeted antioxidant, on mitochondrial and brain injury markers, and the clinical outcomes of patients with ABI. Methods: In this randomized controlled trial, intensive care unit (ICU) or neurology patients with ABI (n=60) received melatonin (21 mg/day) or placebo tablets, within the first 72 hours of injury onset for five days. As a primary endpoint, serum levels of malondialdehyde (MDA), S100B and C-reactive protein (CRP) were compared at baseline, and after five days’ intervention. Secondary endpoints included assessment of Glasgow Coma Scale and Sequential Organ Failure Assessment (at the end of day 5), Rancho Los Amigos Revised Scale and modified Rankin Scale (at the end of month 3), the duration of mechanical ventilation, the lengths of ICU and hospital stays, and in-hospital and three-month mortality. Results: There were no significant effects of melatonin on the primary and secondary outcomes. However, the subgroup analysis showed a significant reduction in S100B in patients with non-traumatic brain injuries, receiving melatonin versus placebo (p: 0.016). Conclusion: This study showed that melatonin supplementation in the early phase of brain injury had no significant effects on the injury markers and clinical outcomes of patients with ABI. However, it reduced the level of S100B in the non-traumatic subgroup. Further larger-scale studies are needed to determine the effects of melatonin on the ABI and its subgroups.
8 June 2024 in DARU Journal of Pharmaceutical Sciences
Purpose: In cases of traumatic brain injury (TBI), oxidative stress is recognized as a major factor in neuronal cell damage. This study aimed to assess the effects of coenzyme Q10 (CoQ10) on oxidative stress biomarkers and clinical outcomes in patients with TBI. Methods: In this randomized controlled trial, patients with moderate or severe TBI (n = 40) admitted to the ICU received either CoQ10 tablets at a dose of 600 mg/day or a placebo for three days within the first 72 hours post-injury. Serum malondialdehyde (MDA) levels and superoxide dismutase (SOD) activity were assessed at baseline and again three days after the intervention. The Glasgow Coma Scale (GCS) was evaluated daily until day 5. The Glasgow Outcome Scale (GOS) was assessed at the time of discharge from both the ICU and hospital, and the Sequential Organ Failure Assessment (SOFA) score was determined on days 1, 3, and 5. Mortality rates and the length of ICU and hospital stays were also recorded. Results: CoQ10 had no significant effect on MDA levels, SOD activity, or duration of hospitalization compared with the placebo (P > 0.05). However, GCS scores showed significant improvement from days 3 to 5 in the CoQ10 group compared with the placebo (P = 0.017, P = 0.007, and P = 0.006, respectively). GOS scores demonstrated significant improvement at discharge from both the ICU and hospital (P = 0.005 and P < 0.001, respectively). In the CoQ10 group, the SOFA score declined significantly by day 5 compared with the placebo (P = 0.023). In-hospital mortality was also significantly lower in the CoQ10 group (P = 0.002). Conclusion: Supplementation with CoQ10 in patients with TBI improved GCS, GOS, and SOFA scores and reduced in-hospital mortality. CoQ10 may serve as a promising adjunctive therapy in TBI patients, although further research is required.